PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Renal Category Valganciclovir Dosing Misses Ganciclovir Target in Most Simulated Patients

ganciclovirvalganciclovircytomegalovirus prophylaxissolid organ transplantkidney transplantpopulation pharmacokineticsMonte Carlo simulationtherapeutic drug monitoringmodel-informed precision dosingCockcroft–GaultMDRDCKD-EPIrenal dose adjustmentAUC target attainment Pharmacokinetics / TDM

Background Information

Renal dosing of valganciclovir often misses target drug exposure.

Ganciclovir exposure variability in renal dosing may lead to suboptimal prophylaxis in transplant patients. MDRD and CKD-EPI reclassified many patients, reducing target attainment to 20-23%, with high underexposure rates. Renal function-based dosing often fails to achieve target exposure, suggesting a need for TDM and model-informed dosing. Current renal dosing for valganciclovir is unreliable; consider exposure-guided dosing strategies.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Maizaud F, Labriffe M, Sayadi H, Belaiche S, Marquet P, Woillard JB, Monchaud C

Citation: Maizaud F, Labriffe M, Sayadi H, et al. Renal Function-Guided Valganciclovir Dosing and Ganciclovir Exposure Variability: A Population Pharmacokinetic Simulation Study. Basic & clinical pharmacology & toxicology. 2026;139(6). doi:10.1111/bcpt.70329

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.